172 related articles for article (PubMed ID: 38103787)
1. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
2. CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases.
Porta F; Comini M; Soncini E; Carracchia G; Maffeis M; Pintabona V; Bolda F; Beghin A; Schumacher RF; Lanfranchi A
Transplant Cell Ther; 2021 May; 27(5):426.e1-426.e9. PubMed ID: 33965183
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
4. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
[TBL] [Abstract][Full Text] [Related]
5. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
6. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawal V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn JY; Cairo M; Castillo P; Chhabra S; Diaz MA; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryan A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Patel SS; Qayed M; Rangarajan HG; Reshef R; Ringden O; Savani BN; Schouten HC; Schultz KR; Seo S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1875-1883. PubMed ID: 31085303
[TBL] [Abstract][Full Text] [Related]
7. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Nagler A; Labopin M; Shimoni A; Niederwieser D; Mufti GJ; Zander AR; Arnold R; Greinix H; Cornelissen JJ; Jackson GH; Craddock C; Bunjes DW; Ganser A; Russell NH; Kyrcz-Krzemien S; Rocha V; Mohty M
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1422-9. PubMed ID: 22446014
[TBL] [Abstract][Full Text] [Related]
8. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; Pearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL
Br J Haematol; 2011 Apr; 153(2):244-52. PubMed ID: 21382020
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
[TBL] [Abstract][Full Text] [Related]
10. CD3
Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
[TBL] [Abstract][Full Text] [Related]
11. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.
Jo T; Arai Y; Kondo T; Mizuno S; Hirabayashi S; Inamoto Y; Doki N; Fukuda T; Ozawa Y; Katayama Y; Kanda Y; Fukushima K; Matsuoka KI; Takada S; Sawa M; Ashida T; Onizuka M; Ichinohe T; Atsuta Y; Kanda J; Yanada M
Cytotherapy; 2022 Oct; 24(10):1013-1025. PubMed ID: 35729020
[TBL] [Abstract][Full Text] [Related]
12. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
14. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
15. Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival.
Ali MM; Grønvold B; Remberger M; Abrahamsen IW; Myhre AE; Tjønnfjord GE; Fløisand Y; Gedde-Dahl T
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):598-605. PubMed ID: 34158268
[TBL] [Abstract][Full Text] [Related]
16. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
Bleakley M; Sehgal A; Seropian S; Biernacki MA; Krakow EF; Dahlberg A; Persinger H; Hilzinger B; Martin PJ; Carpenter PA; Flowers ME; Voutsinas J; Gooley TA; Loeb K; Wood BL; Heimfeld S; Riddell SR; Shlomchik WD
J Clin Oncol; 2022 Apr; 40(11):1174-1185. PubMed ID: 35007144
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study.
Fauser AA; Basara N; Blau IW; Kiehl MG
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S27-31. PubMed ID: 10933183
[TBL] [Abstract][Full Text] [Related]
19. Similar outcomes of peripheral blood stem cells vs. bone marrow for human leukocyte antigen-matched unrelated donor transplantation in adult patients with acute myeloid leukemia using risk-adapted graft-versus-host disease prophylaxis.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Eur J Haematol; 2014 Jul; 93(1):19-28. PubMed ID: 24527665
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q
Front Immunol; 2022; 13():1036403. PubMed ID: 36389692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
